330794-31-5 Usage
General Description
1-cyclopentyl-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine is a chemical compound that belongs to the pyrazolo[3,4-d]pyrimidine class. It is characterized by a cyclopentyl group attached to the nitrogen atom, an iodine atom, and an amine group. 1-cyclopentyl-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine is of interest in medicinal chemistry due to its potential biological activities, such as antitumor and antiviral properties. It may also be used as a building block in the synthesis of novel pharmaceutical agents. The specific properties and potential applications of this compound depend on its structural and chemical characteristics, making it an important target for further research and development in the field of drug discovery and design.
Check Digit Verification of cas no
The CAS Registry Mumber 330794-31-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,0,7,9 and 4 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 330794-31:
(8*3)+(7*3)+(6*0)+(5*7)+(4*9)+(3*4)+(2*3)+(1*1)=135
135 % 10 = 5
So 330794-31-5 is a valid CAS Registry Number.
330794-31-5Relevant articles and documents
FUSED PYRIMIDINE COMPOUND OR SALT THEREOF
-
Paragraph 1505; 1506, (2018/02/06)
The present invention provides a novel RET inhibitor comprising, as an active ingredient, a compound or a salt thereof that have not been known for their RET inhibitory activity, and also provides an agent for preventing or treating diseases (e.g., malign
PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER
-
Paragraph 00231, (2017/05/02)
This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of t
FUSED RING HETEROARYL KINASE INHIBITORS
-
Page/Page column 65-66, (2010/04/30)
Provided herein are fused ring heteroaryl compounds useful in a variety of methods, including reducing the activity of certain kinases and treating certain disease states.